Effects of the jak1-selective inhibitor filgotinib on gene expression profile in blood of patients with active rheumatoid
Những tác giả chính: | Taylor, P, Tarrant, J, Zhao, L, Gindin, Y, Mirza, A, Harrison, P, Tasset, C, Galien, R, Van der Aa, A, Downie, B |
---|---|
Định dạng: | Conference item |
Được phát hành: |
BMJ Publishing Group
2018
|
Những quyển sách tương tự
-
The JAK1-selective inhibitor filgotinib reverses the disease-associated transcriptional profile found in the blood of patients with active rheumatoid arthritis
Bằng: Taylor, P, et al.
Được phát hành: (2018) -
Filgotinib, a JAK1 inhibitor, modulates disease-related biomarkers in rheumatoid arthritis: results from two randomized, controlled phase 2b trials
Bằng: Tarrant, J, et al.
Được phát hành: (2020) -
Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
Bằng: Mark Genovese, et al.
Được phát hành: (2018-03-01) -
Filgotinib, an oral JAK1 selective inhibitor with a rapid onset of action: results from the DARWIN 1 study in methotrexate inadequate response rheumatoid arthritis patients
Bằng: Taylor, P, et al.
Được phát hành: (2017) -
Selective inhibition of Janus kinase 1 (JAK1) by filgotinib modulates the disease-associated whole blood transcriptional profile of patients with active rheumatoid arthritis
Bằng: Taylor, P, et al.
Được phát hành: (2019)